Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Veritone Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B), while Veritone Inc trades at $0.61 (market cap $59.46M). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 987.9× Veritone Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Veritone Inc for 12 Days on average.
| TAK | VERI | |
|---|---|---|
Market Cap | $58.74B | $59.46M |
Volume | 3,110,994 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $19.05 | $8.39 |
52-Week Low | $13.23 | $0.59 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $86.65B | $94.86M |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Veritone (VERI) trades at $0.69, down 7.38% over 24 hours, reflecting ongoing investor concerns. The stock is technically bearish with negative earnings trends, including a net income margin of -117.54% for 2025. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are overshadowed by a securities class action investigation and consistent quarterly losses.
The outlook remains challenging due to persistent unprofitability and high cash burn. The consensus price target of $3.75 offers significant upside if the company can achieve cost reductions and revenue growth, but execution risks and legal overhangs present substantial headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
